论文部分内容阅读
为探讨非类固醇抗雌激素三苯氧胺(TAM)辅助治疗原发性进展期乳腺癌的效果以及与雌激素受体(ER)水平的关系,作者对291名高复发倾向的绝经期后乳腺癌患者进行了研究。患者年龄在50～75岁之间。肿瘤高复发倾向的依据是淋巴结受累、肿瘤直径大于5cm 或侵及皮肤或筋膜。全部患者在乳房切除术后均接受放疗(RT),尔后随机分为对照组(RT 组)及治疗组(RT+TAM 组),TAM 每次10毫克,一日三次,持续48周后随访。肿瘤组织ER 阳性标准是至少含有10fmol/mg 胞质液蛋白.结果:ER 浓度在10～99fmol/mg 之间者,两组各有43例;≥100者,RT 组69例,RT+TAM 组76例。全部231例ER 阳性的患者中,虽然RT+TAM 组的复发率低于RT 组,但无明显统计学差异(P=0.40),而其中ER≥100的患者,RT+TAM 组的无复发生存率明显高于RT 组(P=0.01)ER 阴性(即ER<10)的60例患者,其无复发生存期最短,并与治疗的组别无关。ER 值在10～99之间的两组患者(86例)的无复发生存率均低于ER≥100的RT+TAM 组,而与其中
To investigate the effect of non-steroidal anti-estrogen tamoxifen (TAM) in the adjuvant treatment of primary advanced breast cancer and its relationship with estrogen receptor (ER) levels, the authors performed 291 postmenopausal women with high recurrence-prone postmenopausal breast cancer. Research. The patient is between 50 and 75 years old. High tumor recurrence tendencies are based on the involvement of lymph nodes, tumors larger than 5 cm in diameter, or invading the skin or fascia. All patients received radiotherapy (RT) after mastectomy and were randomly divided into control group (RT group) and treatment group (RT+TAM group). TAM was 10 mg each time, three times a day, followed up for 48 weeks. The ER positive standard for tumor tissue contains at least 10 fmol/mg cytosolic protein. Results: ER concentrations between 10 and 99 fmol/mg, 43 in each, ≥100, RT in 69, RT+TAM 76 cases. In all 231 ER-positive patients, although the recurrence rate was lower in the RT+TAM group than in the RT group, there was no statistically significant difference (P=0.40). Among those patients with ER≥100, the recurrence-free survival of the RT+TAM group The rate was significantly higher in the 60 patients with ER-negative (ie, ER<10) in the RT group (P=0.01) and the shortest recurrence-free survival was not associated with the treated group. The recurrence-free survival rate of the two groups (86 cases) with ER values between 10 and 99 was lower than that of the RT+TAM group with ER≥100.